Reported consent processes and demographics: A substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

HIV Medicine

Volumn 16, Issue S1, 2015, Pages 24-29

  Denning, E ^a   Sharma, S ^a   Smolskis, M ^b   Touloumi, G ^c   Walker, S ^d   Babiker, A ^d   Clewett, M ^e   Emanuel, E ^f   Florence, E ^g   Papadopoulos, A ^h   Sanchez A ⁱ   Tavel, J ^j   Grady, C ^k  

^a UNIVERSITY OF MINNESOTA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d MRC CLINICAL TRIALS UNIT   (United Kingdom)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^h NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j GENENTECH INC   (United States)

^k NATIONAL INSTITUTES OF HEALTH   (United States)

more..

Author keywords

Informed consent; START trial

Indexed keywords

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; DEVICES; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMED CONSENT; LANGUAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL INFORMATION; PATIENT EDUCATION; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; IMMUNOLOGY; PATHOLOGY; PROCEDURES; STANDARDS; TIME FACTOR; TREATMENT OUTCOME;

ANTIRETROVIRUS AGENT;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFORMED CONSENT; MALE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923349745     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12230     Document Type: Article

References (25)

1. Faden R, Beauchamp TA. A History and Theory of Informed Consent. Oxford, Oxford University Press, 1986.
2. Emanuel EJ, Wendler D, Grady C. What makes clinical research ethical? JAMA 2000; 283: 2701-2711.
3. Bergler JH, Pennington AC, Metcalfe M etal. Informed consent: how much does the patient understand? Clin Pharmacol Ther 1980; 27: 435-439.
4. Howard JM, DeMets D, BHAT Research Group. How informed is informed consent? The BHAT experience. Control Clin Trials 1981; 2: 287-303.
5. Harrison K, Vlahov D, Jones K etal. Medical eligibility, comprehension of the consent process, and retention of injection drug users recruited for an HIV vaccine trial. J Acquir Immune Defic Syndr 1995; 10: 386-390.
6. van Stuijvenberg M, Suur MH, de Vos S etal. Informed consent, parental awareness, and reasons for participating in a randomised controlled study. Arch Dis Child 1998; 79: 120-125.
7. Pace C, Emanuel EJ, Chuenyam T etal. The quality of informed consent in a clinical research study in Thailand. IRB 2005; 27: 9-17.
8. Pace C, Talisuna A, Wendler D etal. Quality of parental consent in a Ugandan malaria study. Am J Public Health 2005; 95: 1184-1189.
9. Moodley K, Pather M, Myer L. Informed consent and participant perceptions of influenza vaccine trials in South Africa. J Med Ethics 2005; 3: 727-732.
10. Karim QA, Karim SSA, Coovadia HM etal. Informed consent for HIV testing in a South African hospital: is it truly informed and truly voluntary? Am J Public Health 1998; 488: 637-640.
11. Leach A, Hilton S, Greenwood BM etal. An evaluation of the informed consent procedure used during a trial of a Haemophilus influenzae type B conjugate vaccine undertaken in The Gambia, West Africa. Soc Sci Med 1999; 48: 139-148.
12. Lynoe N, Hyder Z, Chowdhury M etal. Obtaining informed consent in Bangladesh. N Engl J Med 2001; 344: 460-461.
13. Joubert G, Steinberg H, van der Ryst E etal. Consent for participation in the Bloemfontein vitamin A trial: how informed and voluntary? Am J Public Health 2003; 93: 582-584.
14. Marshall PA, Adebamowo CA, Adeyemo AA etal. Voluntary participation and informed consent to international genetic research. Am J Public Health 2006; 96: 1989-1995.
15. Taub HA, Baker MT, Sturr JF. Informed consent for research. Effects of readability, patient age, and education. J Am Geriatr Soc 1986; 34: 601-606.
16. Davis TC, Holcombe RF, Berkel HJ etal. Informed consent for clinical trials: a comparative study of standard versus simplified forms. J Natl Cancer Inst 1998; 90: 668-674.
17. Coyne CA, Xu R, Raich P etal. Randomised, controlled trial of an easy-to-read informed consent statement for clinical trial participation: a study of the Eastern Cooperative Oncology Group. J Clin Oncol 2003; 21: 836-842.
18. Dresden GM, Levitt MA. Modifying a standard industry clinical trial consent form improves patient information retention as part of the informed consent process. Acad Emerg Med 2001; 8: 246-252.
19. Young DR, Hooker DT, Freeberg FE. Informed consent documents: increasing comprehension by reducing reading level. IRB 1990; 12: 1-5.
20. NCI Template Consent Form, Available at http://ctep.cancer.gov/protocolDevelopment/informed_consent.htm (accessed 13 March 2014).
21. Babiker AG, Emery S, Fätkenheuer G etal. Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials 2013; 10 (Suppl 1): S5-S36.
22. U.S. National Archives and Records Administration. Code of federal regulations. 2005. Title 45. Public Welfare.
23. Sharma S, Babiker AG, Emery S etal. Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. HIV Med 2015; 16 (Suppl 1): 30-36.
24. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004; 292: 1593-1601.
25. INSIGHT START Study Group. Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. HIV Med 2015; 16 (Suppl 1): 1-9.